A Study On The Usability Of The Freestyle Libre
The Freestyle Libre is a product to monitor the blood sugar (glucose) levels without taking blood from the body (a non-invasive procedure).
A study on the usability of the Freestyle Libre flash glucose monitoring system shown the following details.
The Trial Of Drug-Device Combination, Called ITCA 650
The positive results from the 52 weeks, Phase 3, FREEDOM-2 clinical trial of ITCA 650, an injection-free GLP-1 receptor agonist was presented by Intarcia Therapeutics, Inc to the American Diabetes Association (ADA) on June 12th, 2016.
A patient can draw the type 2 diabetes drug exenatide, without any interruption, from osmotic mini-pump that will be placed under the skin.
Metformin may fail to lower HbA1c and body weight in some patients of type 2 diabetes.
A trial of the trial of drug-device combination, called ITCA 650 on those patients has got better results when compared with Januvia in lowering of HbA1c and body weight. The drug was successful in that trial.
Dr. Julio Rosenstock, MD, was the lead investigator of the study.
Approval Of Diabetes Drug Jardiance
An advisory panel of United States Food and Drug Administration (FDA) has concluded that the diabetes drug Jardiance (manufactured by Eli Lilly & Co and Boehringer Ingelheim) can cut the risk of cardiovascular death.
The diabetes drug Jardiance was approved in 2014 to lower blood sugar (glucose) levels in patients with type 2 diabetes (T2D). Now, the drug manufacturer is seeking approval of the drug for the treatment of heart attack and stroke.
A Trial Of Invokana
A study of the diabetes drug invokana as an add-on therapy was conducted on the patients of diabetes using metformin. The study shows a reduction in the body weight and blood pressure and an improvement in the glycemic control.
The study was presented to the American Association of Clinical Endocrinologists (AACE).
Devices From Medtronic
The Medtronic has developed an artificial pancreas called MiniMed 670G (and filed for the FDA approval). This device can eliminate the routine finger prick blood testing, calculation of insulin dosage and injection of insulin.
The device can help the patients of either type 1 diabetes (T1D) or type 2 diabetes (T2D) who require insulin to control blood sugar (glucose) levels.
The device is of a size of the Smartphone and can connect to an insulin pump and glucose monitor without a cable or wire. The equipment will remain outside the body and will take place of the malfunctioning organ of the body to produce insulin, which helps us in converting the sugar in the blood to energy.
The MiniMed 670G system (new artificial pancreas) will administer or withhold microdoses of insulin to keep the patient with diabetes in a predetermined blood sugar target range after checking blood sugar (glucose) levels for every five minutes.
The Trial Of Diabetes Drug Toujeo
Diabetes drug Toujeo manufactured by Sanofi is long-acting insulin for patients of both type 1 (T1D) and type 2 diabetes (T2D).
Sanofi has recently released the evaluation report of the diabetes drug Toujeo with patients of type 2 diabetes (T2D).
The report was presented at the 76th scientific sessions of the American Diabetes Association (ADA), New Orleans.
The evaluation report has indicated an overall success in switching from another basal insulin to diabetes drug Toujeo.
The Clinical Trial Of DNA-Based Gene Therapy VM202, From VM BioPharma
VM BioPharma, the United States is a division of ViroMed Co., Ltd, South Korea. VM202 is a proprietary DNA based BioPharmaceutical drug for the patients of diabetes with the painful diabetic peripheral neuropathy (DPN).
The high blood sugar (glucose) levels in a patient of diabetes can damage the nerves, mostly in lower limbs of the body. The damage to nerves may cause a sudden and severe pain known as diabetic peripheral neuropathy (DPN).
Currently, there is no drug, medication or treatment for diabetic peripheral neuropathy (DPN). The diabetic peripheral neuropathy (DPN) is affecting between 5 and 20 percent of patients of diabetes. Controlling the blood sugar (glucose) levels is the only option to lower the risk of diabetic peripheral neuropathy (DPN).
This drug can promote the microvasculature and can regenerate the nerve cells. The cells in the human body will produce a protein called (human) hepatocyte growth factor (HGF) when drug VM202 is injected into the muscle. The human hepatocyte growth factor (HGF) can help in the formation of new blood vessels.
The VM BioPharma has announced that they are going to start a phase 3 clinical study, a first pivotal gene therapy for the evaluation of the drug VM202. The phase 2 clinical trial of the drug VM202 for patients of diabetes shows a significant and rapid reduction in the pain associated with diabetic peripheral neuropathy (DPN).
Investigator of the Phase 3 study is Dr. Jack Kessler M.D. He is a professor in Neurology, Feinberg School of Medicine, Northwestern University.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. The published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.